Download PDF
Semin Neurol 2013; 33(03): 307-308
DOI: 10.1055/s-0033-1354604
Erratum
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Teriflunomide for the Treatment of Multiple Sclerosis

Jiwon Oh
1   Department of Neurology, Johns Hopkins University, Baltimore, Maryland
2   Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
,
Paul W. O'Connor
1   Department of Neurology, Johns Hopkins University, Baltimore, Maryland
› Author Affiliations
Further Information

Publication History

Publication Date:
21 September 2013 (online)

    Permissions and Reprints

Correction to:

Teriflunomide for the Treatment of Multiple SclerosisSemin Neurol 2013; 33(01): 045-055
DOI: 10.1055/s-0033-1343795

The publisher regrets an error in in the above article in Seminars in Neurology, Volume 33, Number 1, 2013, page 53, DOI:10.1055/s-0033-1343795. In the first paragraph, there is an error in the units given in the sentence, “Females who are taking teriflunomide with plans to conceive must undergo a cholestyramine or activated charcoal-based washout procedure after treatment discontinuation, and must confirm that the plasma level is at a level that presents minimal teratogenic risk (< 0.02 g/L) prior to conceiving.” The units should be “mg/L” rather than “g/L.”